Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: March 3, 2016
Context: The filing discloses a potential grant award notification received by the company's wholly-owned subsidiary, Capricor, Inc., from the California Institute for Regenerative Medicine (CIRM).
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, margins, debt, or liquidity). The only financial figure disclosed is a potential grant amount:
- Potential Grant Award: Approximately $3.38 million.
- Intended Use: Funding for the Phase I/II HOPE-Duchenne clinical trial investigating CAP-1002 for Duchenne Muscular Dystrophy-related cardiomyopathy.
Material Changes
There are no reported material changes to historical financial performance or operations in this filing. The material event is the notification of a recommended grant award, which is contingent upon final approval.
Guidance, Outlook, and Risks
Conditions Precedent: The award is subject to final approval by the Application Review Subcommittee of the Independent Citizens' Oversight Committee of CIRM and the satisfaction of other conditions. Terms and disbursement schedules have not yet been determined.
Forward-Looking Statements: The filing includes a cautionary note that statements regarding the potential receipt of the grant and future expectations are forward-looking and subject to risks. Actual results may differ materially from expectations.
Risk References: Investors are directed to the company's Form 10-K (filed March 16, 2015), Form S-3 (filed September 28, 2015), and Form 10-Q (filed November 13, 2015) for detailed risk factors.
Investor Verification Checklist
- Confirm whether the CIRM Application Review Subcommittee has granted final approval for the $3.38 million award.
- Verify the specific terms and disbursement schedule of the grant once finalized.
- Review the referenced Form 10-K, S-3, and 10-Q filings for existing liquidity constraints and operational risks.
- Monitor the progress of the Phase I/II HOPE-Duchenne clinical trial for CAP-1002.